The New York Node of the CTN is a consortium of academic centers, clinical programs and local and regional agencies with a long track record of fruitful collaboration in research, training, service delivery, policy-making, funding and advocacy for the addictive disorders. The consortium offers a rich array of human talent and has access to vast clinical and policy resources in NY City, NY State and regionally. Together, these investigators, providers and policy-makers have extensive large-scale clinical trials expertise, a broad range of research interests, unique treatment capacity and extensive services and policy experience. Over the past five years the NY Node has built effective internal and external working relationships, it has contributed to the national CTN infrastructure, it has built a solid and flexible local infrastructure and it has effectively implemented protocols as a Lead Node and as a Participating Node. The NY Node played a key role in organizing NIDA's NY Blending Conference in March, 2002, and has successfully worked with emerging local coalitions to foster dissemination and adoption of CTN innovations. NY Node providers and researchers are involved in planning and developing three studies (START, ADHD and prescription opiate analgesic dependence protocols) that will be of high priority for NIDA over the next few years and our CTPs are all well positioned to test and introduce medical interventions. The present proposal is contextualized by five years of CTN experience and by our assessment of the accomplishments of, and challenges facing, the CTN. Our overall thematic approach capitalizes on CTN and Node accomplishments to-date and addresses challenges for the future. We bring in new investigators and expertise, we describe an enhanced science-to-practice model for CTN studies, we expand relationships with state and local government agencies to enable this, and we propose a research concept that works within this framework. Themes include reaching out to primary-care providers, extending relevant outcomes, partnering with agencies that can share study costs and foster adoption, and addressing systems of reimbursement and organization of care. Our research concept builds on these themes to extend the reach of the CTN and to enhance the likelihood that CTN studies will have impact and lead to improved healthcare on a broader level.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10DA013046-10
Application #
7681721
Study Section
Special Emphasis Panel (ZDA1-MXG-S (02))
Program Officer
Dobbins, Ronald
Project Start
2000-02-20
Project End
2013-02-28
Budget Start
2009-09-01
Budget End
2013-02-28
Support Year
10
Fiscal Year
2009
Total Cost
$1,250,000
Indirect Cost
Name
New York University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Crist, R C; Doyle, G A; Nelson, E C et al. (2018) A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18:173-179
Crist, Richard C; Li, James; Doyle, Glenn A et al. (2018) Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse 44:431-440
Lee, Joshua D; Nunes, Edward V; Mpa, Patricia Novo et al. (2016) NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. Contemp Clin Trials 50:253-64
Nunes, Edward V; Lee, Joshua D; Sisti, Dominic et al. (2016) Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. Contemp Clin Trials 51:34-43
Ling, Walter; Hillhouse, Maureen P; Saxon, Andrew J et al. (2016) Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction 111:1416-27
Clarke, T-K; Crist, R C; Ang, A et al. (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:303-8
Bogenschutz, Michael P; Donovan, Dennis M; Mandler, Raul N et al. (2014) Brief intervention for patients with problematic drug use presenting in emergency departments: a randomized clinical trial. JAMA Intern Med 174:1736-45
Morgan-Lopez, Antonio A; Saavedra, Lissette M; Hien, Denise A et al. (2013) Synergy between seeking safety and twelve-step affiliation on substance use outcomes for women. J Subst Abuse Treat 45:179-89

Showing the most recent 10 out of 55 publications